Literature DB >> 32532479

Risk of type III secretion systems in burn patients with Pseudomonas aeruginosa wound infection: A systematic review and meta-analysis.

Meysam Hasannejad-Bibalan1, Alireza Jafari2, Hoda Sabati3, Rajendra Goswami4, Zakiyeh Jafaryparvar5, Farzaneh Sedaghat6, Hadi Sedigh Ebrahim-Saraie7.   

Abstract

PURPOSE: The pathogenesis of Pseudomonas aeruginosa is multifactorial and attributed to the production of several cell-associated and extracellular virulence factors including those implicated in adherence, iron uptake, exoenzymes (Exo) and exotoxins. The present study aimed to determine the prevalence of type III secretion systems (T3SS) effectors in Iranian burn patients with P. aeruginosa wound infection.
METHODS: A systematic search was conducted to identify papers published by Iranian authors in the Web of Science, PubMed, Scopus, Embase, and Google Scholar electronic databases during the period of January, 2000 to December, 2018. Publications which met our inclusion criteria were selected for data extraction and analysis by Comprehensive Meta-Analysis Software. The inclusion criteria were articles that include burn patients with a wound infection caused by P. aeruginosa, and reported the prevalence of aimed exoenzymes.
RESULTS: Ten publications were selected out of 15 full-text reviewed articles with the inclusion criteria. Of ten studies, the pooled prevalence of ExoS producing isolates was estimated at 57.1% (95% CI: 40.3-72.5%). Five studies reported the prevalence of ExoU and ExoT, from which, the pooled prevalence of ExoU and ExoT producing isolates was estimated at 51.4% (95% CI: 31.4-70.9%) and 86.4% (95% CI: 48.1-97.8%), respectively. Four studies reported the prevalence of ExoY, from which, the pooled prevalence of ExoY producing isolates was estimated at 79.0% (95% CI: 48.6-93.8%).
CONCLUSION: Our results showed a remarkable prevalence of T3SS-positive genotype in patients with burn injuries. These findings provided attractive targets for new therapeutic strategies for burn patients who were infected with cytotoxin-producing P. aeruginosa.
Copyright © 2020 Elsevier Ltd and ISBI. All rights reserved.

Entities:  

Keywords:  Burn patients; Exoenzymes; Pseudomonas aeruginosa; Wound infection

Year:  2020        PMID: 32532479     DOI: 10.1016/j.burns.2020.04.024

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  5 in total

1.  Relationship of biofilm-forming ability of with swimming motility, twitching motility and virulence gene distribution.

Authors:  Jian Shui; Haichen Wang; Xiaoyan Tao; Changhang Min; Jun Li; Mingxiang Zou
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-06-25

2.  Evaluation of the Effect of Comprehensive and Targeted Surveillance on Nosocomial Infections in Nephrology Patients.

Authors:  Jiali Zheng; Jiuying Fei; Hongbo Li; Yan Xu
Journal:  J Healthc Eng       Date:  2022-04-29       Impact factor: 3.822

3.  Clonal Clusters, Molecular Resistance Mechanisms and Virulence Factors of Gram-Negative Bacteria Isolated from Chronic Wounds in Ghana.

Authors:  Denise Dekker; Frederik Pankok; Thorsten Thye; Stefan Taudien; Kwabena Oppong; Charity Wiafe Akenten; Maike Lamshöft; Anna Jaeger; Martin Kaase; Simone Scheithauer; Konstantin Tanida; Hagen Frickmann; Jürgen May; Ulrike Loderstädt
Journal:  Antibiotics (Basel)       Date:  2021-03-22

4.  Adaptation to an Amoeba Host Leads to Pseudomonas aeruginosa Isolates with Attenuated Virulence.

Authors:  Wai Leong; Wee Han Poh; Jonathan Williams; Carla Lutz; M Mozammel Hoque; Yan Hong Poh; Benny Yeo Ken Yee; Cliff Chua; Michael Givskov; Martina Sanderson-Smith; Scott A Rice; Diane McDougald
Journal:  Appl Environ Microbiol       Date:  2022-01-12       Impact factor: 4.792

5.  Clinical Observation of Helicobacter pylori Infection and Risk Factors and Cytotoxin-Associated Protein A in Patients with Coronary Heart Disease.

Authors:  Xiaoyuan Wang; Meiling Du; Fangjiang Li
Journal:  Contrast Media Mol Imaging       Date:  2022-08-17       Impact factor: 3.009

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.